C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in C4 Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 84
- −15 vs. Q2 2023
- Shares held
- 34.5M
- +299.1K (+0.9%) vs. Q2 2023
- Total value
- $64.5M
- −$29.6M (−31.5%) vs. Q2 2023
- New holders
- 7
- 30 more added
- Sold out
- 22
- 32 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −12,708−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −11,686−100.0% | Sold out |
| SEI Investments Co | 0 | $0 | 0.00% | −11,191−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −10,900−100.0% | Sold out |
| Erste Asset Management GmbH | 0 | $0 | 0.00% | −10,700−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −320−100.0% | Sold out |
| Endurance Wealth Management, Inc. | – | – | – | – | Not filed |